$599

Lilly Oral GLP-1RA with Chugai

Lilly announced it has in-licensed the global development and commercialization rights to Chugai’s non-peptidic GLP-1RA, which is ready to enter Ph1. Below, FENIX provides more details and insight on the deal, especially in the context of Novo’s oral semaglutide.

This content is for Read Less members only.
Register
Already a member? Log in here